<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1326">
  <stage>Registered</stage>
  <submitdate>11/10/2006</submitdate>
  <approvaldate>11/10/2006</approvaldate>
  <nctid>NCT00387725</nctid>
  <trial_identification>
    <studytitle>Study Evaluating Safety &amp; Immunogenicity of rLP2086 Vaccine in Adolescents</studytitle>
    <scientifictitle>A Randomized, Observer-blinded, Parallel-group, Active-control, Phase Â½ Trial Of The Safety, Immunogenicity, And Tolerability Of 20 Mg, 60 Mg, And 200 Mg Of Meningococcal Group B Rlp2086 Vaccine In Healthy Children And Adolescents Aged 8 To 14 Years</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>B1971006</secondaryid>
    <secondaryid>6108A1-501</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - rLP2086
Other interventions - rLP2086
Other interventions - rLP2086
Other interventions - rLP2086

Experimental: Group A - 20ug Experimental

Experimental: Group 2 - 60ug Experimental

Experimental: Group 3 - 200ug Experimental

Active Comparator: Group 4 - Active comparator


Other interventions: rLP2086
Vaccine administered at 0, 1, and 6 months

Other interventions: rLP2086
Vaccine administered at 0, 1, and 6 months

Other interventions: rLP2086
Vaccine administered at 0, 1, and 6 months

Other interventions: rLP2086
Vaccine administered at 0, 1, and 6 months

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Participants With Seroconversion in rLP2086 Specific Serum Bactericidal Assay (SBA) Titer 1 Month After Dose 2</outcome>
      <timepoint>1 month after Dose 2</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants With Seroconversion in rLP2086 Specific SBA Titer 1 Month After Dose 3</outcome>
      <timepoint>1 month after Dose 3</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants With at Least One Adverse Event (AE)</outcome>
      <timepoint>Dose 1 up to 1 month after Dose 3</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          -  Aged 8 to 14 years at the time of enrollment.

          -  Healthy male or female subjects

          -  Negative urine pregnancy test for female subjects</inclusivecriteria>
    <inclusiveminage>8</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>14</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          -  Prior vaccination with a meningococcal B vaccine

          -  Prior meningococcal disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>127</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,WA</recruitmentstate>
    <hospital>Sydney Children's Hospital - Randwick</hospital>
    <hospital>The Children's Hospital at Westmead - Westmead</hospital>
    <hospital>Royal Children's Hospital - Herston</hospital>
    <hospital>Princess Margaret Hospital for Children - Subiaco</hospital>
    <hospital>Sir Albert Sakzewski Virus Research Centre (SASVRC) - Herston</hospital>
    <hospital>Women's &amp; Children's Hospital - North Adelaide</hospital>
    <hospital>The Telethon Institute for Child Health Research - Subiaco</hospital>
    <hospital>National Centre for Immunisation - Westmead</hospital>
    <hospital>Department of Paediatrics and Child Health - Woden</hospital>
    <postcode>2031 - Randwick</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4006 - Herston</postcode>
    <postcode>6008 - Subiaco</postcode>
    <postcode>QLD 4006 - Herston</postcode>
    <postcode>SA 5006 - North Adelaide</postcode>
    <postcode>WA 6008 - Subiaco</postcode>
    <postcode>NSW 2145 - Westmead</postcode>
    <postcode>ACT 2606 - Woden</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Study to evaluate the safety of an investigational meningitis vaccine and the immune response
      to it in adolescents</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00387725</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>